- Home
- TOVX
as 06-27-2025 2:33pm EST
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 3.8M | IPO Year: | 2006 |
| Target Price: | N/A | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $7.37 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Theriva Biologics Inc. News
TOVX Breaking Stock News: Dive into TOVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
GlobeNewswire
a month ago
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
Associated Press Finance
a month ago
Theriva Biologics: Q1 Earnings Snapshot
GlobeNewswire
2 months ago
Theriva Biologics Announces Closing of $7.5 Million Public Offering
GlobeNewswire
2 months ago
Theriva Biologics Announces Pricing of $7.5 Million Public Offering
GlobeNewswire
2 months ago
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients
GlobeNewswire
3 months ago
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
GlobeNewswire
3 months ago
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Compare TOVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TOVX Theriva Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.